A new tumor marker for Ovarian Cancer

卵巢癌的新肿瘤标志物

• 批准号: 7389433
• 负责人: MADHWA H.G RAJ
• 金额: $ 7.1万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-02-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7389433
• 关键词: Age; Biological Models; Breast; Bypass Budget; CA-125 Antigen; Case-Control Studies; Cervix Uteri; Clinic; Data; Detection; Disease; Endometrium; Epithelial ovarian cancer; Estrogens; Growth and Development function; Gynecology; Health Sciences; Malignant Neoplasms; Malignant neoplasm of ovary; Measures; Medical center; Menopausal Status; Menstrual cycle; Molecular Profiling; Pattern; Performance; Premenopause; Property; Proteins; Race; Recruitment Activity; Role; Serum; Signal Transduction; Staging; Statistically Significant; Techniques; Testing; Tumor Markers; Tumor Tissue; University Hospitals; Woman; cancer cell; case control; day; riboflavin-binding protein; size; tumor molecular fingerprint

Cancer cells possess unique cellular signatures which signal the presence of the disease. This property can be potentially used as a marker to detect the presence of the cancer. Riboflavin Carrier Protein (RCP) is an estrogen induced growth and development specific protein. We hypothesize that serum levels of RCP can be used to accurately and non- invasively detect ovarian epithelial cancer and other cancers unique to women such as those of the breast, endometrium and cervix. In this project we will test this hypothesis using ovarian epithelial cancer as a model system. In a preliminary study of 6 women, we found that mean RCP levels were 3.5 ng/ml for state I and 11.2 ng.m. for state III ovarian cancer, as compared to 0.7 ng/ml for healthy subjects. Although the study size is small, the differences are highly statistically significant with p values for difference less than 0.05. In the present proposal, we will prospectively confirm our preliminary results in a case control study. We will recruit incident ovarian cancer cases from clinics at LSU Health Sciences Center, University Hospital and Memorial Medical Center. Control subjects not having any cancer will be recruited from Gynecology clinics and will be matched 1.1 for race, age, menopausal status and if pre-menopausal, for day of menstrual cycle. Serum RCP levels will be tested on both cases and controls at entry into the study. We will attempt to confirm our preliminary data that serum, RCP levels can accurately detect early ovarian epithelial cancer and predict its stage. We will also measure the serum levels of CA-125, a marker that is currently being used even though it is elevated in only about 50% of ovarian cancers. We will compare performance of RCP test with CA-125 test in order to evaluate the superiority of the former in predicting early ovarian cancer. We will compare performance of RCP test with CA-125 test in order to evaluate the superiority the former in predicting early ovarian cancer. Finally, using immunohistochemical techniques, we will characterize expression patterns of RCP in epithelial ovarian cancer tumor tissue. Our preliminary studies suggest a role of RCP as a molecular signature indicative of the present of ovarian cancer. The RCP test will be a valuable application of the use of cancer cell signatures as detection markers, which is a critical component of the 2001 Bypass Budget Document of NCI.

癌细胞具有独特的细胞信号，表明疾病的存在。这一特性可能被用作检测癌症存在的标记。核黄素载体蛋白(RCP)是雌激素诱导的生长发育特异性蛋白。我们假设血清RCP水平可用于准确和非侵入性地检测卵巢上皮癌和其他女性特有的癌症，如乳腺癌、子宫内膜癌和子宫颈癌。在这个项目中，我们将使用卵巢上皮癌作为模型系统来检验这一假说。在对6名女性的初步研究中，我们发现状态I的RCP平均水平为3.5 ng/ml，而状态I的平均RCP水平为11.2 ng/ml。对于状态III的卵巢癌，与之相比，健康受试者为0.7 ng/ml。虽然研究规模不大，但差异具有高度统计学意义，差异的p值小于0.05。在目前的提案中，我们将在病例对照研究中前瞻性地确认我们的初步结果。我们将从路易斯安那州立大学健康科学中心、大学医院和纪念医学中心的诊所招募卵巢癌病例。未患癌症的对照受试者将从妇科诊所招募，并将种族、年龄、绝经状态与1.1匹配，如果是绝经前，则匹配月经周期日。在进入这项研究时，将对患者和对照组的血清RCP水平进行测试。我们将尝试确认我们的初步数据，即血清RCP水平可以准确地检测早期卵巢上皮癌并预测其分期。我们还将测量血清CA-125的水平，这是一种目前仍在使用的标记物，尽管只有50%的卵巢癌患者的CA-125水平升高。我们将比较RCP试验和CA-125试验的性能，以评价前者在预测早期卵巢癌方面的优势。我们将比较RCP试验和CA-125试验的性能，以评价前者在预测早期卵巢癌方面的优势。最后，利用免疫组织化学技术，我们将表征RCP在上皮性卵巢癌肿瘤组织中的表达模式。我们的初步研究表明，RCP可以作为卵巢癌存在的分子标志。RCP测试将是使用癌细胞签名作为检测标记的有价值的应用，这是NCI 2001年旁路预算文件的关键组成部分。